Summary
126.92 -2.63(-2.03%)11/18/2025
GeneDx Holdings Corp. (WGS)
WGS reported last earnings on 2025-10-28 after the market. An EPS of $0.49 was observed compared to an estimated EPS of $0.28, resulting in a surprise value of $0.21. A revenue of $117 million was observed compared to an estimated revenue of $121 million, resulting in a surprise value of $-4 Million.
GeneDx Holdings Corp. (WGS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -2.03 | -7.40 | 7.12 | 2.90 | 82.41 | 82.21 | -60.47 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C+ |
| Recommended Rating | Sell |
| DCF | Strong Sell |
| ROE | Neutral |
| ROA | Buy |
| Debt/Equity | Sell |
| P/E | Strong Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 126.92 | |
| Open | 128.99 | |
| High | 131.20 | |
| Low | 125.65 | |
| Volume | 256,078 | |
| Change | -2.63 | |
| Change % | -2.03 | |
| Avg Volume (20 Days) | 622,142 | |
| Volume/Avg Volume (20 Days) Ratio | 0.41 | |
| 52 Week Range | 58.00 - 147.71 | |
| Price vs 52 Week High | -14.07% | |
| Price vs 52 Week Low | 118.83% | |
| Range | 0.00 | |
| Gap Up/Down | -6.96 | |
Profitibility | ||
| Market Capitalization (Mln) | 4,100 | |
| Revenue per share | 13.9660 | |
| Net Income per share | 0.0723 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 1,754.6845 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
11/14 13:51 EST - fool.com
BOSUN Sells All 70K GeneDx Holdings Corp. Shares—Should Investors Follow Suit?
Sold 69,858 shares, reducing stake value by about $6.45 million Post-trade stake in GeneDx Holdings Corp: zero shares, $0 value The position previously comprised 1.9% of the fund's AUM as of the prior quarter
BOSUN Sells All 70K GeneDx Holdings Corp. Shares—Should Investors Follow Suit?
Sold 69,858 shares, reducing stake value by about $6.45 million Post-trade stake in GeneDx Holdings Corp: zero shares, $0 value The position previously comprised 1.9% of the fund's AUM as of the prior quarter
11/11 09:58 EST - fool.com
Artificial Intelligence (AI) Stock Scores Vote of Confidence From Asset Manager, According to Recent Filing
Added 120,000 shares of GeneDx Holdings, an increase valued at ~$12.93 million Post-trade stake: 120,000 shares worth $12.93 million as of September 30, 2025 GeneDx Holdings is not among Telemark Asset Management's top five positions by size
Artificial Intelligence (AI) Stock Scores Vote of Confidence From Asset Manager, According to Recent Filing
Added 120,000 shares of GeneDx Holdings, an increase valued at ~$12.93 million Post-trade stake: 120,000 shares worth $12.93 million as of September 30, 2025 GeneDx Holdings is not among Telemark Asset Management's top five positions by size
11/06 08:00 EST - businesswire.com
GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting.
GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting.
11/06 04:13 EST - defenseworld.net
Y Intercept Hong Kong Ltd Takes $589,000 Position in GeneDx Holdings Corp. $WGS
Y Intercept Hong Kong Ltd bought a new stake in GeneDx Holdings Corp. (NASDAQ: WGS) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,380 shares of the company's stock, valued at approximately...
Y Intercept Hong Kong Ltd Takes $589,000 Position in GeneDx Holdings Corp. $WGS
Y Intercept Hong Kong Ltd bought a new stake in GeneDx Holdings Corp. (NASDAQ: WGS) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,380 shares of the company's stock, valued at approximately...
10/28 15:41 EST - seekingalpha.com
GeneDx Holdings Corp. (WGS) Q3 2025 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sabrina Dunbar Katherine Stueland - President, CEO & Director Kevin Feeley - Chief Financial Officer Bryan Dechairo - Chief Operating Officer Conference Call Participants Subhalaxmi Nambi -...
GeneDx Holdings Corp. (WGS) Q3 2025 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sabrina Dunbar Katherine Stueland - President, CEO & Director Kevin Feeley - Chief Financial Officer Bryan Dechairo - Chief Operating Officer Conference Call Participants Subhalaxmi Nambi -...
10/28 08:46 EST - zacks.com
GeneDx Holdings Corp. (WGS) Q3 Earnings and Revenues Surpass Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.04 per share a year ago.
GeneDx Holdings Corp. (WGS) Q3 Earnings and Revenues Surpass Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.04 per share a year ago.
10/28 06:30 EST - businesswire.com
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2025.
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2025.
10/27 08:00 EST - seekingalpha.com
GeneDx: A Moment Of Reckoning As Market Awaits Q3 Testing Growth
GeneDx Holdings Corp. is poised for strong Q3 results, driven by expanding exome and genome testing in pediatric and neonatal settings. Key metrics for WGS include test volume growth and reimbursement rates, with management targeting a 30% annual volume increase and improving price realization....
GeneDx: A Moment Of Reckoning As Market Awaits Q3 Testing Growth
GeneDx Holdings Corp. is poised for strong Q3 results, driven by expanding exome and genome testing in pediatric and neonatal settings. Key metrics for WGS include test volume growth and reimbursement rates, with management targeting a 30% annual volume increase and improving price realization....
10/27 08:00 EST - prnewswire.com
GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims
SAN FRANCISCO , Oct. 27, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating to whether the company misled investors about its health intelligence platform called Centrellis....
GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims
SAN FRANCISCO , Oct. 27, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating to whether the company misled investors about its health intelligence platform called Centrellis....
10/26 04:38 EST - defenseworld.net
VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in GeneDx Holdings Corp. $WGS
VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of GeneDx Holdings Corp. (NASDAQ: WGS) in the second quarter, according to its most recent filing with the SEC. The firm purchased 5,400 shares of the company's stock, valued at approximately $498,000. A number of other hedge funds...
VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in GeneDx Holdings Corp. $WGS
VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of GeneDx Holdings Corp. (NASDAQ: WGS) in the second quarter, according to its most recent filing with the SEC. The firm purchased 5,400 shares of the company's stock, valued at approximately $498,000. A number of other hedge funds...
10/26 01:37 EST - defenseworld.net
GeneDx Holdings Corp. (NASDAQ:WGS) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of GeneDx Holdings Corp. (NASDAQ: WGS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating and...
GeneDx Holdings Corp. (NASDAQ:WGS) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of GeneDx Holdings Corp. (NASDAQ: WGS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating and...
10/24 09:40 EST - businesswire.com
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. If you currently own GeneDx stock and acquired shares on or before January 18,...
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. If you currently own GeneDx stock and acquired shares on or before January 18,...
10/22 08:00 EST - businesswire.com
GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Showcases Leadership in gNBS at ICoNS 2025 with data from more than 22,000 newborns.
GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Showcases Leadership in gNBS at ICoNS 2025 with data from more than 22,000 newborns.
10/20 08:00 EST - businesswire.com
GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announces that the FDA has granted Breakthrough Device Designation for its whole genome and exome tests.
GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announces that the FDA has granted Breakthrough Device Designation for its whole genome and exome tests.
10/15 15:30 EST - youtube.com
GeneDX CEO Katherine Stueland on how the company is using AI to save lives
GeneDX CEO Katherine Stueland discusses how the company is using AI to help deliver "life-changing information." Want to hear the full interview?
GeneDX CEO Katherine Stueland on how the company is using AI to save lives
GeneDX CEO Katherine Stueland discusses how the company is using AI to help deliver "life-changing information." Want to hear the full interview?
10/15 13:30 EST - youtube.com
GeneDX CEO Katherine Stueland on conquering imposter syndrome
GeneDX CEO Katherine Stueland shares her advice for conquering imposter syndrome with CNBC's Julia Boorstin: "Step into the deep end." Want to hear the full interview?
GeneDX CEO Katherine Stueland on conquering imposter syndrome
GeneDX CEO Katherine Stueland shares her advice for conquering imposter syndrome with CNBC's Julia Boorstin: "Step into the deep end." Want to hear the full interview?
10/15 11:45 EST - youtube.com
GeneDX CEO Katherine Stueland on if the cuts at NIH impact the company
GeneDX CEO Katherine Stueland talks about the impact of federal funding cuts to research programs. Want to hear the full interview?
GeneDX CEO Katherine Stueland on if the cuts at NIH impact the company
GeneDX CEO Katherine Stueland talks about the impact of federal funding cuts to research programs. Want to hear the full interview?
10/15 09:15 EST - prnewswire.com
Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map variants SAN DIEGO , Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that...
Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map variants SAN DIEGO , Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that...
10/15 02:55 EST - seekingalpha.com
GeneDx's Blueprint For The Next Healthcare Revolution
GeneDx Holdings is transforming into a global genetic software leader, leveraging its vast database and recent Fabric Genomics acquisition. WGS achieved strong Q2 results: 49% revenue growth, 71% gross margin, positive cash flow, and raised full-year guidance, signaling accelerating adoption. The...
GeneDx's Blueprint For The Next Healthcare Revolution
GeneDx Holdings is transforming into a global genetic software leader, leveraging its vast database and recent Fabric Genomics acquisition. WGS achieved strong Q2 results: 49% revenue growth, 71% gross margin, positive cash flow, and raised full-year guidance, signaling accelerating adoption. The...
10/14 15:17 EST - youtube.com
How GeneDX CEO Katherine Stueland is using AI to save lives
She started her career helping launch breakthrough treatments for HIV and cancer. Today, Katherine Stueland is leading GeneDx — a genetic testing company using genomic insights to diagnose rare diseases faster and more accurately than ever before.
How GeneDX CEO Katherine Stueland is using AI to save lives
She started her career helping launch breakthrough treatments for HIV and cancer. Today, Katherine Stueland is leading GeneDx — a genetic testing company using genomic insights to diagnose rare diseases faster and more accurately than ever before.
Market News
×
Loading news…